Men who underwent prostate-specific antigen (PSA) screening before their diagnosis were significantly more likely to be diagnosed with early-stage prostate cancer compared to those without prior screening. A new analysis of real-world health records examined nearly 8,000 prostate cancer patients and found that prior PSA testing was associated with a 52% higher likelihood of catching cancer at an earlier, more treatable stage.

What Does This Study Tell Us About PSA Screening?

Researchers at Truveta analyzed health records from more than 1.2 million men with prostate cancer diagnoses between 2018 and 2025, focusing on 7,996 patients who had detailed clinical information available. The key finding was striking: 42.8% of patients with prior PSA screening were diagnosed at an early stage, compared to just 37.6% of those without prior screening. This difference held true even after accounting for age, race, ethnicity, where patients lived, and other health factors.

The association was particularly strong in two groups. Among men aged 55 to 69 years, the age range where shared decision-making about screening is recommended, those with prior PSA screening were 43% more likely to be diagnosed early. Even more notably, men aged 70 and older, a group where routine screening is generally discouraged, showed a 55% higher likelihood of early-stage diagnosis if they had been screened.

Why Does Earlier Detection Matter for Prostate Cancer?

Catching cancer at an earlier stage typically means the disease is still localized to the prostate gland, making it easier to treat and associated with better long-term outcomes. Advanced-stage prostate cancer, by contrast, requires more intensive treatment and carries a worse prognosis. In this study, 40% of patients were diagnosed at an early stage, while 59.6% had advanced-stage disease. The implication is that PSA screening may shift the balance toward earlier, more manageable diagnoses.

However, the researchers emphasized that these findings must be considered alongside the known tradeoffs of PSA screening. While screening can detect cancer earlier, it can also identify slower-growing tumors that may never cause harm, potentially leading to unnecessary biopsies and treatments. Additionally, elevated PSA levels can result from common prostate conditions unrelated to cancer, so a high result alone does not confirm malignancy.

How Should Men Approach PSA Screening Decisions?

• Understand Your Age and Risk: The U.S. Preventive Services Task Force recommends shared decision-making discussions about PSA screening for men aged 55 to 69 years, while men aged 70 and older are generally advised against routine screening. The American Cancer Society suggests that screening discussions may begin at age 40 for men at higher risk of developing prostate cancer.
• Know the Screening Window: This study defined prior PSA screening as any test performed between three years and six months before a prostate cancer diagnosis, a timeframe that captures routine screening rather than diagnostic testing done after symptoms appear.
• Have a Conversation With Your Doctor: Modern screening recommendations emphasize shared decision-making, where patients and physicians discuss both the potential benefits of early detection and the risks of overdiagnosis and overtreatment. This personalized approach helps men make informed choices aligned with their values and health status.

What Changed in Prostate Cancer Screening Practices?

The landscape of PSA screening has shifted significantly over the past decade. In 2012, the U.S. Preventive Services Task Force recommended against PSA screening for all men, citing concerns about overdiagnosis. This recommendation led to a decline in screening rates and, correspondingly, an increase in advanced-stage prostate cancer diagnoses. In 2018, the guidance was updated to support shared decision-making for men aged 55 to 69 years, and PSA screening rates began to increase again.

This new study provides insight into how screening practices have evolved since that 2018 shift. By analyzing data from 2018 to 2025, researchers could examine whether the return to shared decision-making has translated into earlier diagnoses at the patient level. The finding that prior PSA screening is associated with earlier-stage diagnosis suggests that screening, when used thoughtfully, may help identify cancer before it progresses.

The researchers noted several limitations of their analysis. They did not evaluate downstream outcomes such as overdiagnosis or overtreatment following diagnosis, nor did they assess how frequently patients underwent PSA screening, which could influence detection timing. Additionally, PSA screening performed outside participating health systems may not have been captured in the data. Despite these limitations, the study leveraged a large, diverse dataset with detailed clinical information, providing a real-world perspective on how screening relates to stage at diagnosis.

For men considering prostate cancer screening, these findings underscore the importance of an informed conversation with a healthcare provider. While this study demonstrates that prior screening is associated with earlier detection, the decision to screen should weigh individual risk factors, age, overall health, and personal preferences about the potential benefits and harms of testing and treatment.